Clinical trials: Stress Disorder, Post-Traumatic
- Condition Stress Disorder, Post-Traumatic
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Posttraumatic Stress Disorder
Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD
The goal of this clinical trial is to learn if MDMA in combination with therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01793610
- Testing
- Comparator Dose (40mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Active Dose 1 (125 mg) MDMA HCl
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel
The goal of this clinical trial is to learn if MDMA-assisted therapy can treat PTSD in participants with PTSD. Researchers will compare two sessions of MDMA-assisted therapy with two sessions of low dose (active placebo)…
- Trial name
- NCT00402298
- Testing
- Full Dose Midomafetamine HCl, Low Dose Midomafetamine HCl
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with at least severe PTSD. The main question it aims to answer is: Do three sessions of MDMA-assisted therapy reduce PTSD…
- Trial name
- NCT03537014
- Testing
- Therapy, midomafetamine HCl
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD.
- Trial name
- MPVA6 (NCT04784143)
- Testing
- Midomafetamine, Psychotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Posttraumatic Stress Disorder
Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with at least severe PTSD.
- Trial name
- NCT03485287
- Testing
- Midomafetamine HCl, Manualized therapy
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Resilient Pharmaceuticals
PTSD
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
This is an open-label, extension trial designed to evaluate safety over 12 additional weeks of TNX-102 SL therapy taken daily at bedtime for the treatment of PTSD.
- Trial name
- NCT03110575
- Testing
- TNX-102 SL
- Where
- 32 sites in United States
- Volunteers
- 190 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Stress Disorders, Post-Traumatic
EEG Personalized Transcranial Magnetic Stimulation (eTMS) for Post-Traumatic Stress Disorder
This is an open-label safety pilot study of the Electroencephalogram (EEG) Transcranial Magnetic Stimulation (eTMS) treatment for Post-Traumatic Stress Disorder (PTSD).
- Trial name
- NCT06081309
- Testing
- EEG-based personalized TMS
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wave Neuroscience
Posttraumatic Stress Disorder
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
- Trial name
- NCT00353938
- Testing
- 3,4-methylenedioxymethamphetamine (125 mg), 3,4-methyelendioxymethamphetamine (25 mg), Therapy
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Resilient Pharmaceuticals
Post Traumatic Stress Disorder
A Study to Assess the Use of Methylone in the Treatment of PTSD
This study is evaluating the safety, tolerability, and efficacy of methylone in adults with PTSD. The study will be conducted in two parts.
- Trial name
- IMPACT-1 (NCT05741710)
- Testing
- Methylone
- Where
- 16 sites in United States, Ireland and 1 more
- Volunteers
- 79 people
- Sponsor
- Transcend Therapeutics
PTSD
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine.
- Trial name
- HONOR (NCT03062540)
- Testing
- TNX-102 SL
- Where
- 44 sites in United States
- Volunteers
- 358 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
COVID-19, Pregnancy Complications
Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
- Conditions
- COVID-19, Pregnancy Complications, Mental Health Wellness 1, Anxiety
- Trial name
- NCT04385238
- Testing
- This is an online survey with no intervention.
- Where
- United States
- Volunteers
- 6,894 people
- Sponsor
- Pregistry
Post Traumatic Stress Disorder
Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD
This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult participants with Post-Traumatic Stress Disorder.
- Trial name
- NCT04124614
- Testing
- Brexpiprazole, Sertraline
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Post-traumatic Stress Disorder, PTSD
Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
To evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (PAR) or sertraline (SER) on PTSD symptoms.
- Trial name
- NCT01987960
- Testing
- Brexpiprazole
- Where
- 59 sites in United States, Estonia and 7 more
- Volunteers
- 417 people
- Sponsor
- H. Lundbeck A/S
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Posttraumatic Stress Disorder
Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD
The goal of this clinical trial is to compare full dose MDMA-assisted therapy to placebo with therapy in participants with chronic, treatment-resistant PTSD.
- Trial name
- NCT01958593
- Testing
- Midomafetamine HCl, Psychotherapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Resilient Pharmaceuticals
Post-Traumatic Stress Disorder
A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
This study is open to people aged 18 to 65 who have post-traumatic stress disorder. The purpose of this study is to find out whether a medicine called BI 1358894 improves symptoms in people with post-traumatic stress disorder.
- Trial name
- NCT05103657
- Testing
- BI 1358894
- Where
- 61 sites in United States, Croatia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
PTSD
A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine.
- Trial name
- RECOVERY (NCT03841773)
- Testing
- TNX-102 SL
- Where
- 30 sites in United States
- Volunteers
- 192 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Stress Disorders, Post-Traumatic
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
To evaluate the safety, efficacy and tolerability of brexpiprazole (with placebo) as monotherapy or combination therapy with Zoloft (sertraline) in adults with PTSD.
- Trial name
- NCT03033069
- Testing
- Brexpiprazole, Sertraline
- Where
- 54 sites in United States
- Volunteers
- 336 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Post Traumatic Stress Disorder
An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD
This study is evaluating the safety and efficacy of methylone in adults with PTSD. The study is conducted in two parts. Part A is open-label and will enroll up to 15 participants with PTSD Part B is randomized (1:1:1)…
- Trial name
- IMPACT-2 (NCT06215261)
- Testing
- Methylone
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 62 people
- Sponsor
- Transcend Therapeutics
PTSD
Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions
This is a 12-week, multicenter, open-label extension study to evaluate the safety and efficacy of TNX-102 SL tablet taken daily at bedtime in patients with Military-Related PTSD or related condition.
- Trial name
- P202 (NCT02421679)
- Testing
- TNX-102 SL
- Where
- 22 sites in United States
- Volunteers
- 159 people
- Sponsor
- Tonix Pharmaceuticals, Inc.